The incretin effect — the observation that oral glucose produces a greater insulin response than equivalent intravenous glucose — was first described in 1964. Yet 60 years later, we still don't fully understand the nutrient sensing mechanisms in enteroendocrine L-cells that trigger GLP-1 secretion. Let me set the stage with the quantitative framework: > "The incretin effect accounts for approximately 50-70% of the total insulin secretory response to oral glucose in healthy individuals, with GLP-1 and GIP contributing roughly equal proportions. In type 2 diabetes, the incretin effect is reduced to approximately 20-35%, primarily due to impaired GLP-1-stimulated insulin secretion rather than reduced GLP-1 secretion per se." > — Nauck et al., *Diabetologia*, 1986; 29:46–52 Key L-cell biology facts: - L-cells are primarily located in the ileum and colon (but also in the jejunum and duodenum in smaller numbers) - They are "open-type" enteroendocrine cells — apical surface faces the gut lumen, basolateral surface faces the lamina propria - They contain granules with GLP-1, GLP-2, PYY, and oxyntomodulin (all derived from proglucagon processing) - They can sense nutrients via the luminal (apical) surface AND receive neural/hormonal signals via the basolateral surface The central question I want to discuss: how does a nutrient in the gut lumen trigger GLP-1 release from an L-cell? What are the molecular sensors?

The molecular nutrient sensors on L-cells are remarkably diverse. This is an active research area with many recent discoveries. Here's the current landscape: Glucose sensing: 1. SGLT1 (SLC5A1): Sodium-glucose co-transporter. Na⁺/glucose influx → depolarization → voltage-gated Ca²⁺ entry → granule exocytosis. This is probably the PRIMARY glucose sensor in L-cells. 2. GLUT2 (SLC2A2): Facilitative glucose transporter. Glucose → glycolysis → ATP → KATP channel closure → depolarization. Same mechanism as β-cells but less important in L-cells. 3. Sweet taste receptors (T1R2/T1R3): Yes, L-cells express taste receptors! Glucose → T1R2/T1R3 → gustducin → PLCβ2 → IP3 → Ca²⁺ release. This explains why artificial sweeteners can trigger some GLP-1 release. > "SGLT1-mediated glucose sensing is the dominant mechanism for glucose-stimulated GLP-1 secretion, as demonstrated by the 65% reduction in GLP-1 response to oral glucose in SGLT1-knockout mice and the abolition of glucose-stimulated GLP-1 secretion by the SGLT1 inhibitor phlorizin in perfused rat intestine." > — Gorboulev et al., *Diabetes*, 2012; 61(1):187–196 Fatty acid sensing: 1. FFAR1 (GPR40): Long-chain fatty acid receptor → Gq → PLC → Ca²⁺ → secretion 2. FFAR4 (GPR120): Long-chain fatty acid receptor (similar pathway) 3. GPR119: Oleoylethanolamide receptor → Gs → cAMP → secretion 4. Bile acid receptor (GPBAR1/TGR5): Conjugated bile acids → Gs → cAMP → GLP-1 secretion Amino acid/protein sensing: 1. CaSR (calcium-sensing receptor): Aromatic amino acids → Gq → PLC → secretion 2. GPRC6A: Basic amino acids → Gq signaling 3. PepT1 (SLC15A1): Di/tripeptide transporter → depolarization

Excellent comprehensive overview. I want to zoom in on two particularly interesting sensing mechanisms: 1. The bile acid → TGR5 → GLP-1 axis: This is clinically relevant because it may partly explain the GLP-1 surge after bariatric surgery. After Roux-en-Y gastric bypass: - Bile acids reach the distal gut more rapidly (altered anatomy) - Higher bile acid concentrations in the ileum/colon - Increased TGR5 activation on L-cells - Enhanced GLP-1 secretion > "Roux-en-Y gastric bypass surgery increased postprandial GLP-1 levels by 5-10-fold compared to pre-surgical values, with the magnitude of GLP-1 increase correlating with total bile acid concentrations (r=0.68, P<0.001), implicating enhanced bile acid-TGR5 signaling as a mechanism for post-surgical incretin enhancement." > — Patti et al., *Diabetes*, 2009; 58(9):2048–2050 This also explains why bile acid sequestrants (colesevelam) improve glycemic control — they increase bile acid cycling to the distal gut, enhancing TGR5-mediated GLP-1 release. 2. Gut microbiome → L-cell signaling: Short-chain fatty acids (SCFAs: acetate, propionate, butyrate) produced by gut bacterial fermentation of fiber activate FFAR2 (GPR43) and FFAR3 (GPR41) on L-cells: > "Propionate stimulated GLP-1 secretion from murine colonic L-cells via FFAR2/Gq signaling, with an EC₅₀ of 120 μM — a concentration readily achieved in the colonic lumen during fiber fermentation. Germ-free mice showed 40% lower fasting GLP-1 levels that were restored by colonization with SCFA-producing bacteria." > — Tolhurst et al., *Diabetes*, 2012; 61(2):364–371

The temporal dynamics of GLP-1 secretion are also important for understanding the incretin effect. There are actually TWO phases: Early phase (5-15 min post-meal): - GLP-1 rises rapidly, even before nutrients reach the ileum - Mechanism: vagal reflexes (duodenal nutrient sensing → vagal afferent → vagal efferent → proximal L-cell activation) - Also: proximal gut L-cells (yes, there are some in the duodenum/jejunum) directly sense nutrients Late phase (30-120 min post-meal): - Sustained GLP-1 elevation as nutrients reach the ileum/colon - Mechanism: direct luminal nutrient sensing by distal L-cells (SGLT1, FFAR1, TGR5, etc.) - This phase is quantitatively larger > "The biphasic GLP-1 response to meal ingestion consists of an early peak at 10-15 minutes (mediated by neural reflexes and proximal L-cells) and a sustained elevation from 30-120 minutes (mediated by direct distal L-cell nutrient sensing), with the late phase contributing approximately 70% of total GLP-1 secretion." > — Herrmann et al., *Endocrinology*, 1995; 136(11):5182–5188 The neural reflex component: Duodenal nutrient detection → vagal afferent (CCK release, 5-HT from enterochromaffin cells) → NTS → vagal efferent → ACh release → M1/M3 receptors on L-cells → GLP-1 secretion. This "long reflex" explains the early-phase GLP-1 surge.

I want to highlight an emerging concept that's changing our understanding of L-cell biology: enteroendocrine cell plasticity. Traditional view: L-cells are terminally differentiated cells with fixed hormone expression patterns. New view: Enteroendocrine cells exist on a continuum and can change their hormone expression profile in response to metabolic conditions. > "Single-cell RNA sequencing of human intestinal enteroendocrine cells revealed that individual cells frequently co-express multiple hormone transcripts (e.g., GCG/PYY/CCK), challenging the traditional classification of discrete L-cell, I-cell, and K-cell populations and supporting a model of multi-hormonal enteroendocrine cells with plastic hormone expression." > — Beumer et al., *Cell, 2020; 181(6):1291–1306 Clinical relevance: In obesity and T2DM, the enteroendocrine cell landscape may be altered: - Reduced L-cell density in the proximal gut - Altered hormone co-expression patterns - Decreased sensitivity of nutrient sensors (SGLT1, FFARs) This could contribute to the impaired incretin effect in T2DM — not just β-cell resistance to GLP-1, but also reduced GLP-1 secretion from dysfunctional L-cells.